TRAW
Traws Pharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$12.47M
P/E Ratio
—
EPS
$-1.82
Beta
1.62
52W High
$3.27
52W Low
$0.97
50-Day MA
$1.92
200-Day MA
$1.89
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. The company is headquartered in Newtown, Pennsylvania.
Fundamentals
| Revenue (TTM) | $2.85M |
| Gross Profit (TTM) | $2.85M |
| EBITDA | $-15.77M |
| Operating Margin | -555.00% |
| Return on Equity | -1060.00% |
| Return on Assets | -92.30% |
| Revenue/Share (TTM) | $0.43 |
| Book Value | $0.64 |
| Price-to-Book | 2.92 |
| Price-to-Sales (TTM) | 4.38 |
| EV/Revenue | 2.405 |
| EV/EBITDA | 0.33 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 4695.00% |
| Shares Outstanding | $7.99M |
| Float | $3.80M |
| % Insiders | 19.83% |
| % Institutions | 42.78% |
Historical Volatility
HV 10-Day
82.88%
HV 20-Day
99.50%
HV 30-Day
85.24%
HV 60-Day
133.42%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($7.25 target)
2
BuyData last updated: 4/9/2026